MedTrace Logo

Covid-19 Vaccine Responses in Patients With Inflammatory Bowel Diseases

NCT05067959 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 284

Last updated 2021-10-05

No results posted yet for this study

Summary

The 2019-coronavirus disease (COVID-19), caused by SARS-CoV-2, was identified as the source of pneumonia cases in Wuhan city in China. It rapidly spread worldwide and was declared by WHO as a pandemic. COVID-19 vaccines are expected to be the breakthrough in controlling the pandemic. However, studies performed only in healthy adults, and specifically excluded patients who were under immunomodulatory/biologic therapy, thus excluding patients with chronic inflammatory diseases (IBD). In this study we wish to understand vaccine efficacy and immunological response in IBD patients.

Conditions

Interventions

BIOLOGICAL

Covid-19 vaccine

blood tests and questioners before 1st vaccine, 3 weeks before 2nd vaccine, 4 weeks after 2nd vaccine, 6 months after 1st vaccine, and 12 months after 2nd vaccine

Sponsors & Collaborators

  • Shaare Zedek Medical Center

    collaborator OTHER

  • Soroka University Medical Center

    collaborator OTHER

  • Emek Medical Center

    collaborator OTHER

  • Rabin Medical Center

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-28
Primary Completion
2021-12-31
Completion
2022-03-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05067959 on ClinicalTrials.gov